Press releaseGlobe Newswire
Lyell Immunopharma
LYEL · NASDAQ
$9.70+$0.90 (+10.23%)TodayMarket closed ·
Prev close $8.80
Latest news
- Press releaseGlobe Newswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
- Press releaseGlobe Newswire
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
- NewsVandana Singh
Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update
- News
Lyell Immunopharma Issues LYL273 Safety Profile Update In Its Ongoing U.S. Phase 1 Clinical Trial In Patients With Relapsed Or Refractory Metastatic Colorectal Cancer
- Press releaseGlobe Newswire
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
- News
Earnings Scheduled For May 6, 2026
- Press releaseGlobe Newswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
- Press releaseGlobe Newswire
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
- Press releaseGlobe Newswire
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
- Press releaseGlobe Newswire
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
- Press releasePRNewswire
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releasePRNewswire
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
- News
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts
- NewsVandana Singh
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
- NewsAvi Kapoor
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- NewsAvi Kapoor
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.